A Study to Assess Relatlimab in Combination With Nivolumab in Chinese Participants With Advanced Solid Tumors

• Status: Not yet recruiting
• Trial end date: 2024-10-06
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the safety, drug levels, immunogenicity and preliminary efficacy of BMS-986213 (relatlimab/nivolumab fixed-dose combination) in Chinese participants with advanced solid tumors.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb

Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit: www.BMSStudyConnect.com

Inclusion Criteria:

• Presence of at least one lesion with measurable disease as defined by RECIST v1.1 criteria for response assessment

• Participants must have received, and then progressed, or been intolerant to at least one standard treatment regimen in the advanced or metastatic setting, if such a therapy exists

• ECOG status of 0 or 1

• Life expectancy of ≥ 12 weeks at the time of informed consent per Investigator assessment

Exclusion Criteria:

• Participants with history of severe and/or life-threatening toxicity related to prior immune therapy (eg, anti-CTLA-4 or anti-PD-1/PD-L1 treatment or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways)

• Participants with an active, known or suspected autoimmune disease

• Participants with primary CNS tumors

Other protocol-defined inclusion/exclusion criteria apply